Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coherus Insists Demand Is ‘Pent Up’ For On-Body Pegfilgrastim Biosimilar

As Company Plots ‘Very Careful Review Over Time’ For Udenyca PFS

Executive Summary

California-Based Coherus BioSciences delved further into its plans and expectations for its proposed proprietary pegfilgrastim on-body device, as it also detailed continued pricing challenges for the pre-filled syringe formulation.

You may also be interested in...



Fresenius Delayed By FDA Inspection Uncertainty As It Works Towards US Pegfilgrastim Launch

Ali Ahmed, senior vice president of biosimilars at Fresenius Kabi, considers the launch of the firm’s proposed Neulasta (pegfilgrastim) biosimilar in the US “an important milestone for the company.” However, he explains in an exclusive interview with Generics Bulletin, delays to necessary FDA inspections are creating uncertainty for the firm over launch timing.

Coherus Partners Formycon/Bioeq File Ranibizumab With FDA

Launch planning is underway for the Lucentis biosimilar that Coherus BioScienes has in-licensed in the US from Formycon and Bioeq, the US-based firm has revealed, as the eye-disease biologic was submitted to the US Food and Drug Administration.

Coherus Gets Goal Date On US Adalimumab Biosimilar

A further FDA approval for a biosimilar to Humira could be on the cards, after Coherus revealed the agency’s goal date for its CHS-1420 adalimumab application.

Topics

Related Companies

UsernamePublicRestriction

Register

GB151406

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel